The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | MAIC of zanubrutinib and venetoclax + ibrutinib in treatment-naïve CLL
Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, outlines the findings of a matching-adjusted indirect comparison (MAIC) between zanubrutinib and venetoclax + ibrutinib for treatment-naïve chronic lymphocytic leukemia (CLL). When adjusting for all factors, the efficacy of the treatment regimens is comparable. However, treatment with zanubrutinib is associated with a more favorable safety profile despite being administered as a continuous therapy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
